|Researchers whose work is funded by drug companies find that those companies forbid them from mentioning side effects or poor trial outcomes. Researchers often have conflicts of interest and will benefit financially, if a drug does well in studies. So they use strategies that are calculated to make a dodgy drug look good on paper, for profit. For example, they will end a trial early, if they see signs that it is about to reveal side effects or other problems.
A doctor you trust, who keeps up with the most current solutions to the healthcare challenges Americans face, can make all the difference in avoiding or managing chronic illnesses that bedevil people of diverse ethnic or racial groups. But disturbing revelations in recent years raise concerns about the trustworthiness of the sources doctors look to for the latest medical information.
Consider the case of BiDil. In 2005, BiDil, a congestive heart-failure medication, became the first medication approved by the Food and Drug Administration (FDA) for African Americans only. But BiDil is not the “black” drug that medical-journal reports have claimed it is.